| High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements studied in …STUDIED_INderived10 of 16show all (up to 200) |
|---|
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05600686Phase 2 · active not recruiting Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped CURATED_BROADER · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05755087Phase 1 · recruiting Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04323956Phase 1 · active not recruiting Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05908409Phase 1/Phase 2 · recruiting A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies · condition mapped ALIAS · 16 trials mapped (11 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |